From a3b354972abf3049081ca0c754807bd4e8a3287e Mon Sep 17 00:00:00 2001
From: Kaya <kaya.lange@uni-bielefeld.de>
Date: Thu, 21 Nov 2024 20:13:07 +0100
Subject: [PATCH] hp changes

---
 src/data/hptimelinedata.tsx | 5 +++--
 1 file changed, 3 insertions(+), 2 deletions(-)

diff --git a/src/data/hptimelinedata.tsx b/src/data/hptimelinedata.tsx
index 543efa92..4ba982c2 100644
--- a/src/data/hptimelinedata.tsx
+++ b/src/data/hptimelinedata.tsx
@@ -1241,8 +1241,7 @@ export const timelinedata: Array<TimelineDatenpunkt>  = [
     <QaBox q="Is it advisable to modify the lipid components in an existing LNP formulation?" a="It is generally advisable to consider alternative lipid components, as different lipids may offer improved stability or efficacy. However, the specific needs of the project will dictate whether changes are necessary."/>
     <QaBox q="Is it possible to incorporate antibodies into LNPs, and what is the recommended approach?" a="Yes. Incorporation of antibodies into LNPs is possible. This can be achieved either during the initial preparation phase or by incubating antibodies with LNPs after their formation, depending on whether surface or internal localization of antibodies is desired. Reference to specific studies may provide further guidance."/>
     <QaBox q="What is Corden Pharma's position on projects involving gene therapy?" a="Corden Pharma operates as a service provider, focusing on the manufacturing of active pharmaceutical ingredients (APIs) and excipients rather than developing therapeutic products. Consideration should be given to the intellectual property status of the lipids used in LNP formulations, particularly for commercial applications."/>
-    <QaBox q="Is it possible to obtain a discount on LNP starter kits or establish a collaborative relationship with Corden Pharma?" a="We would need to discuss this internally but generally we would be open to potential collaborations that could involve recognition in publications or other forms of acknowledgment, pending approval from relevant management."/>
-    </>,
+   </>,
     summary: "The primary goal of the communication with Steffen Bira and Serra Gürcan from Corden Pharma was to explore the use of Lipid Nanoparticles (LNPs) in gene therapy and inhalation treatments. Corden Pharma recommended consulting specialists for assessing spray drying feasibility, while highlighting the importance of testing LNP stability under various conditions. Their LNP starter kits are optimized for stability and encapsulation efficiency, with potential for lipid modifications to enhance cellular uptake. They also confirmed that antibodies can be incorporated into LNPs and emphasized considering intellectual property when selecting lipids. Based on Corden Pharma’s insights, we switched to their kit #2 for our project,  hoping to improve the stability and efficiency of our LNP formulations. Their guidance also opened opportunities for targeted therapies and collaborations. This feedback will continue to enhance our testing and therapeutic approaches.",
     months: "july",
     pictureurl_interview:"https://static.igem.wiki/teams/5247/photos/hp/hp-corden-zoom.png"
@@ -1341,6 +1340,8 @@ export const timelinedata: Array<TimelineDatenpunkt>  = [
     tag: "Other",
     heading: "Cooperation to create a Lipid Delivery System Handbook",
     interviewtabid: "handbook",
+    job: "iGEM Team",
+    affiliation: "Linköping",
     cardtext: "",
     quoteVorname: "Kaya",
     quoteNachname: "Lange",
-- 
GitLab